BioNTech's Cancer Candidate Delivers as Shareholders Face Capital Vote

BioNTech SE's stock has surged nearly 10% over the past week, trading at 85.20 EUR, as compelling clinical data for a key oncology asset bolsters investor confidence in the company's strategic pivot. The advance comes just weeks before a critical shareholder vote on a substantial capital increase, framing a pivotal moment for the Mainz-based biotech.

The catalyst is robust Phase 2 data for the antibody-drug conjugate Trastuzumab Pamirtecan (BNT323/DB-1303) in advanced, pretreated endometrial cancer. The candidate achieved a confirmed objective response rate of 47.9%, starkly outperforming the typical 15% rate seen with chemotherapy. Median progression-free survival was 8.1 months, with a median duration of response of 10.3 months. In a subset of patients with strong HER2 expression, the response rate soared to 73.1%. The drug already holds FDA Fast Track and Breakthrough Therapy designations, with a Biologics License Application planned for 2026.

Wall Street has taken note. Bank of America recently raised its price target to $130, while Morgan Stanley maintains an "Overweight" rating with a $126 target. Berenberg has reiterated its Buy recommendation. However, not all analysts are uniformly bullish; Leerink Partners downgraded the stock to "Market Perform," lowering its target to $94, citing caution over the revenue gap as COVID-19 vaccine sales decline. Among covering analysts, 13 out of 18 currently recommend buying the shares, with a consensus price target of $133.13.

The clinical success sets the stage for a crucial corporate event. On May 15, BioNTech will hold its virtual Annual General Meeting. A key agenda item is the proposed creation of "Authorized Capital 2026," which would enable the issuance of up to 129.5 million new shares—equivalent to 50% of the current share capital. This move signals the significant funding still required for late-stage cancer trials and other pipeline programs. The meeting will also vote on expanding the Supervisory Board from six to eight members, adding two new specialists in oncology and clinical development.

Should investors sell immediately? Or is it worth buying BioNTech?

Financially, BioNTech remains well-equipped for its ambitious transition, sitting on a massive liquidity reserve of 17.2 billion EUR. Yet the company forecasts a roughly 25% revenue decline for 2026, to between 2.0 and 2.3 billion EUR, as its COVID-19 business continues to shrink. Commercial revenue from new oncology assets is not expected before 2027. The company plans to spend up to 2.5 billion EUR on research and development this year alone, funding nine ongoing Phase 3 oncology studies and six more slated to begin in 2026.

Investors will get a fresh look at the financials when BioNTech reports first-quarter 2026 results on May 5, ten days before the shareholder vote. The coming weeks will test the market's belief in BioNTech's long-term oncology strategy, balancing promising clinical milestones against the immediate financial realities of a post-pandemic transition.

Ad

BioNTech Stock: New Analysis - 16 April

Fresh BioNTech information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech analysis...

Ad

BioNTech's Cancer Candidate Delivers as Stock: New Analysis - 16 April

Fresh BioNTech's Cancer Candidate Delivers as information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.

Read our updated BioNTech's Cancer Candidate Delivers as analysis...